The Role
Lead translational biomarker strategy and validation for clinical candidates: identify and validate pharmacology biomarkers, manage assay validation with CLIA labs/CROs, write SOPs for GSP/GCLP, coordinate with nonclinical teams for NHP and FIH studies, oversee lab operations, training, compliance and audits, and support early-phase dosing/POC biomarker decisions.
Summary Generated by Built In
Senior Scientist, Translational Immunology
Location: South San Francisco, CA (On-site)
Parvus Therapeutics Inc.
Parvus Therapeutics Inc. is a privately held biopharmaceutical company developing Navacims™, a platform technology based on foundational research published in 2016 (Nature 530:434), to treat autoimmune diseases. Parvus’ mission is to shift the treatment paradigm toward Navacim™-directed immune regulation, avoiding non-specific immune suppression associated with current therapies. Parvus’ innovative approach has the potential to benefit millions of patients suffering from debilitating autoimmune diseases and other chronic inflammatory conditions. Parvus is advancing a pipeline of proprietary drug candidates for multiple autoimmune indications through preclinical development and into the clinic. Parvus’ leadership team is experienced in successful drug discovery, development, manufacturing, regulatory approval, and commercialization.
The Position
We are seeking a Senior Scientist to join our team and drive projects enabling the translation, validation, and execution of preclinical biomarkers to the clinic.
Primary Responsibilities:
Location: South San Francisco, CA (On-site)
Parvus Therapeutics Inc.
Parvus Therapeutics Inc. is a privately held biopharmaceutical company developing Navacims™, a platform technology based on foundational research published in 2016 (Nature 530:434), to treat autoimmune diseases. Parvus’ mission is to shift the treatment paradigm toward Navacim™-directed immune regulation, avoiding non-specific immune suppression associated with current therapies. Parvus’ innovative approach has the potential to benefit millions of patients suffering from debilitating autoimmune diseases and other chronic inflammatory conditions. Parvus is advancing a pipeline of proprietary drug candidates for multiple autoimmune indications through preclinical development and into the clinic. Parvus’ leadership team is experienced in successful drug discovery, development, manufacturing, regulatory approval, and commercialization.
The Position
We are seeking a Senior Scientist to join our team and drive projects enabling the translation, validation, and execution of preclinical biomarkers to the clinic.
Primary Responsibilities:
- Identify and validate biomarkers relevant to the pharmacology of target clinical candidates.
- Lead context-of-use validation (in-house or through CLIA-certified laboratories or clinical CROs) of clinical biomarker assays suitable for use in recommended phase 2 dosing selection and/or regulatory submission.
- Write and amend internal SOPs and reports as necessary for GSP or GCLP purposes.
- Liaise with nonclinical pharmacology and discovery immunology teams to establish proof-of-concept/proof-of-mechanism biomarker strategies suitable for use in NHPs and FIH studies.
- Participate in all aspects of lab operation, training, and compliance including external audits where applicable.
- Other duties and responsibilities as assigned.
- Bachelors degree with a minimum 10 years of experience or a Masters degree with a minimum of 6 years of experience (at least 2 years must be in biotech or industry setting) in Immunology or other relevant life sciences. Experience with regulatory T cells or Tr1 cells will be prioritized.
- Expertise in high-dimensional flow cytometry assays including but not limited to spectral flow cytometry and CyTOF.
- Experience leading phase appropriate clinical bioanalytical assay development and analyses including full validation and management of clinical bioanalytical labs/CROs.
- Experience developing lean and agile clinical biomarker budgets suitable for early phase POC and POM studies.
- Nice to have:
- Experience with nanomedicine
- Experience with IQOQ
- Familiarity with biomarker-centric platforms such as spatial profiling, multi-omics integration
- Excellent oral, written communication, and presentation skills.
- Demonstrated ability to effectively work in cross-functional teams, meet deadlines, and prioritize multiple projects is required.
- Comfortable working collaboratively in a small, fast-paced environment.
- Ability to quickly adjust to shifting project demands and priorities.
Skills Required
- Bachelors degree with minimum 10 years experience or Masters with minimum 6 years experience in Immunology or relevant life sciences (≥2 years in biotech/industry)
- Expertise in high-dimensional flow cytometry (including spectral flow cytometry) and CyTOF
- Experience leading clinical bioanalytical assay development, full validation, and management of clinical bioanalytical labs/CROs
- Experience developing clinical biomarker budgets for early phase POC/POM studies
- Experience with lab operations, training, compliance and participation in external audits
- Excellent oral, written, and presentation skills
- Demonstrated ability to work effectively in cross-functional teams, meet deadlines, and prioritize multiple projects
- Experience with regulatory T cells or Tr1 cells
- Experience with nanomedicine
- Experience with IQOQ (Installation/Operational Qualification)
- Familiarity with spatial profiling and multi-omics integration
Am I A Good Fit?
Get Personalized Job Insights.
Our AI-powered fit analysis compares your resume with a job listing so you know if your skills & experience align.
Success! Refresh the page to see how your skills align with this role.
The Company
What We Do
Parvus Therapeutics Inc. is a clinical-stage biopharmaceutical company developing proprietary pMHC nanomedicine drug candidates (Navacims) designed to treat autoimmune diseases. Its mission is to cure autoimmune disease by restoring organ-specific immune tolerance without compromising normal immune function, shifting the treatment paradigm toward Navacim-directed immune regulation to avoid the non-specific immune suppression associated with current therapies.
